User Name Password

back to homepage

NioGold Mining Corp (NOX.V) - continues to produce intriguing gold assays

Comment by Objective Capital , Feb 06, 2009
Click for previous reports on this company
Questions? Contact our analyst

Niogold continues to produce intriguing gold assays from its properties in the Malartic gold camp of western Quebec. This week, the company announced assays from eleven drill holes completed during the 2008 season on the Marban West Extension property. Seven holes yielded noteworthy gold values, led by hole MB-08-091, which produced 11.60 grams of gold over 1.1 metres, and a broader, somewhat deeper zone that produced 2.48 grams of gold over 21.7 metres.

Drill hole MB-08-085 produced 7.20 grams of gold per tonne over a 4.8-metre interval, contained within a 100.8-metre zone that averaged 0.79 gram of gold per tonne. Five other drill holes yielded between 6.25 grams and 10.71 grams of gold per tonne over intervals measuring between 1.1 metres and 1.3 metres in width. Two tests produced assays averaging 3.5 grams of gold per tonne over intervals of 1.0 to 2.4 metres and the final hole failed to intersect significant quantities of gold.

In late January, Niogold produced assays from five holed drilled in the 2008 programme in the area surrounding the Marban mine. Hole MB-08-078 produced 1.78 grams of gold per tonne over 47.4 metres, with higher-grade interval embedded, including a 1.0-metre interval that yielded 42.8 grams of gold per tonne. A second hole, MB-08-080, produced 26.7 grams of gold per tonne over 1.2 metres and a third test, MB-08-081, produced 17.72 grams of gold per tonne over 4.3 metres.

Objective's view:

Niogold has now completed 90 holes into its Marban project since late in 2006 and assays indicate the mineralised zone at Marban is significantly larger than previously believed. At least ten easterly-striking, moderately-dipping mineralised zones are present within an area measuring 1,200 metres long and 350 metres wide, including three newly-recognised features to the north of, and above, the Marban mine.

The latest assays continue to support our base-case valuation for the Marban project and Niogold, albeit within these currently pessimistic times. Also supporting our valuation is Niogold's intention to continue exploration in 2009, commencing with a drill programme in the first quarter designed to test the eastern and vertical extents of the Marban gold system. The work is expected to lead to a formal resource estimate later this year.

SIGN UP NOW FOR OBJECTIVE'S STOCK RESEARCH - IT'S FREE!

Objective, Independent, Experienced.
Research you can trust!

Yes! Subscribe me for the latest stock research from Objective.
Email address
My Password
My information:
First Name
Family Name
Title:
Job title:
Job function:
Industry:
I am a:
 
To receive occasional printed reports complete your mailing address:
 
Company Name (if any)
Address
 
 
City
Postcode/Zip
Country

Please Read Objective's Terms of Use.


Balkan Resources (Private) - exploring the Perlati copper deposit in Albania
Oct 09, 2009 | Previous Reports

Scancell Holdings (SCLP.PLUS) - differentiated technology and a focused plan offer ingredients for success
Sep 08, 2009 | Previous Reports

Sofame Technologies (SDW.V) - ambitious, but high risk growth strategy
Aug 24, 2009 | Previous Reports

Soho Resources (SOH.V) - substantial upgrade to total resource
Aug 19, 2009 | Previous Reports

Colt Resources (COLT.CNQ) - Armamar Meda concession showing good potential
Mar 13, 2009 | Previous Reports

NioGold Mining Corp (NOX.V) - valuation robust despite recession and sector meltdown
Mar 10, 2009 | Previous Reports

Bridge BioResearch (private) - with some glimmer of efficacy, and safety already in evidence, clinical validation could offer lucrative returns
Dec 03, 2008 | Previous Reports

Colt Resources (COLT.CNQ) - Armamar Meda concession showing good potential
Mar 13, 2009 | Previous Reports

NioGold Mining Corp (NOX.V) - valuation robust despite recession and sector meltdown
Mar 10, 2009 | Previous Reports

Bridge BioResearch (private) - with some glimmer of efficacy, and safety already in evidence, clinical validation could offer lucrative returns
Dec 03, 2008 | Previous Reports

e-Therapeutics (ETX.L) - ‘success-predictive’ drug discovery may be the key to new treatment horizons
Nov 18, 2008 | Previous Reports

Great Western Minerals (GWG.V) - pressing ahead with mine-to-market strategy
Nov 07, 2008 | Previous Reports

LiDCO (LID.L) - half year results show early signs of being on track
Oct 30, 2008 | Previous Reports

OCCASIONAL PAPERS

Albania - revisting old frontiers
October, 2008

The rise of independent research (IR Magazine)
March, 2006

Presentation to 2005 AIM Conference
Sept 26, 2005

The Role of Sponsored Research
June 22, 2005

Objective's Corporate Brochure
July 01, 2004

Objective Capital's Contact Information
Partnership, sales and product inquiries: marketing@objectivecapital.co.uk
Media services and conference requests: PR@objectivecapital.co.uk
Subscription and customer service issues: service@objectivecapital.co.uk
Comments or opinions on our analysis: analysis@objectivecapital.co.uk

11-12 Tokenhouse Yard, London EC2R 7AS, United Kingdom
ph +44-(0)870-080 2965 fax +44-(0)870-116 0839

About Us | Contact Us
Latest Analysis | Register Free | Archives
 
Copyright 2004 Objective Capital. All rights reserved.
Terms of Use | Privacy Policy | Disclaimer